Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 19Unknown 14Recruiting 14Terminated 9Withdrawn 3Not yet recruiting 3Suspended 2Active not recruiting 2Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2Recurrence 1

Interventions

Specimen Handling 34Magnetic Resonance Spectroscopy 22Biopsy 20Cyclophosphamide 16Nivolumab 10Paclitaxel 9Cisplatin 9Gemcitabine 8Bevacizumab 8venetoclax 7Vincristine 7Prednisone 7Doxorubicin 7Azacitidine 7pembrolizumab 6Radiotherapy 6Radiosurgery 6Fluorouracil 6Etoposide 6Drug Therapy 6Docetaxel 6Taxes 5Surgical Procedures, Operative 5Rituximab 5Oxaliplatin 5Irinotecan 5Everolimus 5Capecitabine 5fludarabine phosphate 4fludarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Propranolol × Clear all
NCT03384836 2025-07-02

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

Roswell Park Cancer Institute

Phase 1/2 Suspended
47 enrolled
Dermatologic

Melanoma

NCT01988831 2019-05-10

Efficacy of Propranolol Treatment to Prevent Melanoma Progression

University Hospital, Geneva

Phase 2 Suspended
450 enrolled
Dermatologic

Melanoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡